Akynzeo (Netupitant/Palonosetron HCl) Patent Expiration, LOE Window & CMS Spending

Akynzeo (Netupitant/Palonosetron HCl) by Helsinn Healthcare Sa: FDA Orange Book core substance LOE 2035-09-25, 0 AB generics, $444K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHelsinn Healthcare Sa
FDA Application & PathwayN205718 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-09-25
Last Listed Patent or Exclusivity Date2035-09-25
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$444K
2024 Medicare Part D Spend$354K
2024 Medicaid Spend$90K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel